Sign up to save your podcasts
Or
Share S3E2 (#19.1) - Seeing the forest for the trees in Hypertrophic Cardiomyopathy with the SEQUOIA Trial
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S3E2 (#19.1) - Seeing the forest for the trees in Hypertrophic Cardiomyopathy with the SEQUOIA Trial
Join us for a Double Header with the Minnesota Twins! No, we haven't converted to a sports podcast... I have PGY1 Residents (who are identical twins), Kane and Mckay Carstens joining me for back-to-back journal critiques! The first article, the SEQUOIA trial, was conducted to determine the efficacy and safety of aficamten, a novel cardiac myosin inhibitor, in patients with obstructive Hypertrophic Cardiomyopathy (HoCM). Let's get into the weeds to see the forest for the trees - what is aficamten's possible place in therapy for HoCM?
Key Points
- Hypertrophic Cardiomyopathy (HCM) is one of the most common genetic heart conditions worldwide
- Historical pharmacologic treatments are aimed at symptom resolution, but there have not been agents that directly target the mechanism of disease
- Cardiac myosin inhibitors are a new class of drugs on the block with promise for patients with HoCM
- But what do hierarchical secondary outcomes tell us? ------> Tune in to find out!
References
-
[EPISODE TRIAL] Maron MS, Masri A, Nassif ME, et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy [SEQUOIA-HCM]. NEJM 2024;390:1849-1861.
- Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. NEJM 2018.379:655-668.
- Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2024;149:e1239-e1311.
- Laporte S, Divine M, Girault D, et al. What usage and what hierarchical order for secondary endpoints? Therapie 2016,71(1):35-41.
CPR Certification Links
American Heart Association CPR & First Aid: https://cpr.heart.org/en/course-catalog-search
HeartCert: https://heartcertcpr.com/
Contact Information
Podcast email: [email protected]
Host Information
Dr. Diana R. Langworthy, PharmD, BCPS
Clinical Associate Professor, University of Minnesota College of Pharmacy
Clinical Pharmacist - Inpatient Internal Medicine, M Health Fairview East Bank Hospital
Co-Host Information
Kane Carstens, PharmD
PGY1 Resident, University of Minnesota Medical Center East Bank
Mckay Carstens, PharmD
PGY1 Resident, University of Minnesota Medical Center East Bank
View all episodes
By Diana LangworthyJoin us for a Double Header with the Minnesota Twins! No, we haven't converted to a sports podcast... I have PGY1 Residents (who are identical twins), Kane and Mckay Carstens joining me for back-to-back journal critiques! The first article, the SEQUOIA trial, was conducted to determine the efficacy and safety of aficamten, a novel cardiac myosin inhibitor, in patients with obstructive Hypertrophic Cardiomyopathy (HoCM). Let's get into the weeds to see the forest for the trees - what is aficamten's possible place in therapy for HoCM?
Key Points
- Hypertrophic Cardiomyopathy (HCM) is one of the most common genetic heart conditions worldwide
- Historical pharmacologic treatments are aimed at symptom resolution, but there have not been agents that directly target the mechanism of disease
- Cardiac myosin inhibitors are a new class of drugs on the block with promise for patients with HoCM
- But what do hierarchical secondary outcomes tell us? ------> Tune in to find out!
References
-
[EPISODE TRIAL] Maron MS, Masri A, Nassif ME, et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy [SEQUOIA-HCM]. NEJM 2024;390:1849-1861.
- Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. NEJM 2018.379:655-668.
- Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2024;149:e1239-e1311.
- Laporte S, Divine M, Girault D, et al. What usage and what hierarchical order for secondary endpoints? Therapie 2016,71(1):35-41.
CPR Certification Links
American Heart Association CPR & First Aid: https://cpr.heart.org/en/course-catalog-search
HeartCert: https://heartcertcpr.com/
Contact Information
Podcast email: [email protected]
Host Information
Dr. Diana R. Langworthy, PharmD, BCPS
Clinical Associate Professor, University of Minnesota College of Pharmacy
Clinical Pharmacist - Inpatient Internal Medicine, M Health Fairview East Bank Hospital
Co-Host Information
Kane Carstens, PharmD
PGY1 Resident, University of Minnesota Medical Center East Bank
Mckay Carstens, PharmD
PGY1 Resident, University of Minnesota Medical Center East Bank